Results suggested that all therapies had little to no effect on pain and other patient-important outcomes .
Our findings are inconsistent with major clinical practice guidelines ; the available evidence suggests no beneficial effects of any therapies that research ers have evaluated in r and omized controlled trials
BACKGROUND AND PURPOSE Central poststroke pain is a chronic neuropathic disorder that follows a stroke .
Current research on its management is limited , and no review has evaluated all therapies for central poststroke pain .
Daily repetitive transcranial magnetic stimulation of primary motor cortex for neuropathic pain: A randomized, multicenter, double-blind, crossover, sham-controlled trial
& NA ; The double‐blinded r and omized controlled trial showed that daily repetitive transcranial magnetic stimulation of primary motor cortex provided short‐term positive effect on neuropathic pain without serious adverse events . & NA ; There is little evidence for multisession repetitive transcranial magnetic stimulation ( rTMS ) on pain relief in patients with neuropathic pain ( NP ) , although single‐session rTMS was suggested to provide transient pain relief in NP patients . We aim ed to assess the efficacy and safety of 10 daily rTMS in NP patients . We conducted a r and omized , double‐blind , sham‐controlled , crossover study at 7 centers . Seventy NP patients were r and omly assigned to 2 groups . A series of 10 daily 5‐Hz rTMS ( 500 pulses/session ) of primary motor cortex ( M1 ) or sham stimulation was applied to each patient with a follow‐up of 17 days . The primary outcome was short‐term pain relief assessed using a visual analogue scale ( VAS ) . The secondary outcomes were short‐term change in the short form of the McGill pain question naire ( SF‐MPQ ) , cumulative changes in the following scores ( VAS , SF‐MPQ , the Patient Global Impression of Change scale [ PGIC ] , and the Beck Depression Inventory [ BDI ] ) , and the incidence of adverse events . Analysis was by intention to treat . This trial is registered with the University hospital Medical Information Network Clinical Trials Registry . Sixty‐four NP patients were included in the intention‐to‐treat analysis . The real rTMS , compared with the sham , showed significant short‐term improvements in VAS and SF‐MPQ scores without a carry‐over effect . PGIC scores were significantly better in real rTMS compared with sham during the period with daily rTMS . There were no significant cumulative improvements in VAS , SF‐MPQ , and BDI . No serious adverse events were observed . Our findings demonstrate that daily high‐frequency rTMS of M1 is tolerable and transiently provides modest pain relief in NP patients
Results suggested that all therapies had little to no effect on pain and other patient-important outcomes .
Our findings are inconsistent with major clinical practice guidelines ; the available evidence suggests no beneficial effects of any therapies that research ers have evaluated in r and omized controlled trials
BACKGROUND AND PURPOSE Central poststroke pain is a chronic neuropathic disorder that follows a stroke .
Current research on its management is limited , and no review has evaluated all therapies for central poststroke pain .